AbbVievsPacira BioSciences

ABBV and PCRX stock compared: price, dividend, valuation and results, from SEC filings.

AbbVie (ABBV) has a market value of $506B and Pacira BioSciences (PCRX) $1.5B. The P/E is 49.1 for ABBV and 39.2 for PCRX. Dividend yield: ABBV 2.42%, PCRX none.

At a glance

The main figures of both. A bar only shows which number is larger, not which is better.

  • Market value

    ABBV$506B

    PCRX$1.5B

    ABBV is 342 times PCRX

  • Revenue, 12 months

    ABBV$66.0B

    PCRX$743M

    ABBV is 89 times PCRX

  • Net income, 12 months

    ABBV$10.3B

    PCRX$38M

    ABBV is 274 times PCRX

  • Operating margin

    ABBV32.2%

    PCRX4.8%

    27.4 points apart

  • ROIC

    ABBV25.7%

    PCRX2.4%

    23.3 points apart

  • P/E

    ABBV49.1

    PCRX39.2

    ABBV is 1.3 times PCRX

  • Dividend yield

    ABBV2.4%

    PCRX0.0%

    2.4 points apart

A fainter bar means a negative number. The 5-year return includes dividends.

The price over time

Both start at 100 at the beginning of the period, so the lines show how much each changed. With dividends means each dividend buys more shares.

Prices are not available right now.

Each cell: the total return with dividends, its yearly rate, and the price change alone. Before taxes and costs. Past returns do not predict future ones.

Every figure

As on each company's page. A description, not a recommendation: no one figure says which is better.

ABBVAbbViePCRXPacira BioSciences

Valuation

ABBVPCRX
Valuation
Price$286.01$36.48
Market value$506B$1.5B
Enterprise value (EV)$576B$1.5B
P/E49.139.2
P/E, 5-year median57.0–
P/B–2.1
EV/EBIT27.141.2
Free cash flow yield3.7%11.4%

Results and growth

ABBVPCRX
Results and growth
Revenue, 12 months$66.0B$743M
Net income, 12 months$10.3B$38M
Free cash flow, 12 months$18.9B$169M
Earnings per share, 12 months$5.81$0.93
Revenue growth, year on year8.6%3.6%
Revenue growth a year, past+5.9%over 5 years+11.1%over 5 years
EPS growth a year, past-2.8%over 5 years-45.5%over 5 years

Margins and returns on capital

ABBVPCRX
Margins and returns on capital
Gross margin73.7%78.7%
Operating margin32.2%4.8%
Net margin15.7%5.1%
ROIC25.7%2.4%
ROE–5.5%

Balance sheet

ABBVPCRX
Balance sheet
Cash$10.8B$296M
Total debt$80.9B$340M
Net debt / EBITDA3.2-0.0
Interest cover7.1×2.5×

Dividends and buybacks

ABBVPCRX
Dividends and buybacks
Dividend yield2.4%–
Dividend per share, 12 months$6.92–
Dividend growth a year, past+6.6%over 5 years–
Buyback yield0.2%10.0%
Shareholder yield2.6%10.0%

Last 12 months from the latest 10-Q and 10-K. Value, P/E and yields at today's price. A dash means the figure does not exist or did not pass our checks.

Questions: ABBV or PCRX

Didn't find what you were looking for?

Ask us
Which is bigger, AbbVie or Pacira BioSciences?

By market value, AbbVie ($506B) is about 342.4 times Pacira BioSciences ($1.5B), at today's prices.

Which pays the higher dividend, ABBV or PCRX?

The dividend yield at today's price is 2.42% for AbbVie and none for Pacira BioSciences. Over the last twelve months they paid $6.92 and – per share.

What is the P/E of ABBV and PCRX?

At today's price, the P/E is 49.1 for ABBV and 39.2 for PCRX. It is the share price over the last twelve months' earnings per share.

Which has the higher profit margins, AbbVie or Pacira BioSciences?

Over the last twelve months, the net margin was 15.7% for AbbVie and 5.1% for Pacira BioSciences, and the operating margin 32.2% and 4.8%. Revenue was $66.0B and $743M.

Which is the better investment, AbbVie or Pacira BioSciences?

The page does not answer that and does not suggest buying or selling. It puts the two companies' numbers side by side, from their SEC filings, for you to read and form your own view. The decision depends on your goals and situation.

Other comparisons

With each of the two, and with the largest in its sector.

Related pages

The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.

Descriptive data from SEC filings and market prices.